US2010022467A1PendingUtilityA1
Anti-cancer phosphonate analogs
Est. expiryApr 25, 2023(expired)· nominal 20-yr term from priority
Inventors:Constantine G. BoojamraCarina E. CannizzaroJames M. ChenXiaowu ChenAesop ChoLee S. ChongMaria FardisAlan X. HuangChoung U. KimThorsten A. KirschbergSteven KrawczykChristopher P. LeeKuei-Ying LinRichard L. MackmanDavid Y. MarkevitchPeter H. NelsonDavid A. OareVidya K. PrasadHyung-Jung PyunAdrian S. RaySundaramoorthi SwaminathanWilliam J. WatkinsJennifer R. ZhangLijun Zhang
A61P 35/00A61K 31/7076A61K 31/675A61K 31/7072A61K 47/548C07H 19/04
57
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention is related to phosphorus substituted anti-cancer compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
Claims
exact text as granted — not AI-modified1 . A conjugate of the formula:
[DRUG]-(A 0 ) nn ; or a pharmaceutically acceptable salt or solvate thereof;
wherein:
DRUG is a compound of formula 557:
wherein:
nn is 1, 2 or 3;
A 0 is A 1 , A 2 or W 3 with the proviso that the conjugate includes at least one A 1 ;
Y 1 is independently O, S, N(R x ), N(O)(R x ), N(OR x ), N(O)(OR x ), or N(N(R x )(R x ));
Y 2 is independently a bond, O, N(R x ), N(O)(R x ), N(OR x ), N(O)(OR x ), N(N(R x )(R x )), —S(O) M2 —, or —S(O) M2 —S(O) M2 —; and when Y 2 joins two phosphorous atoms Y 2 can also be C(R 2 )(R 2 );
R x is independently H, R 1 , R 2 , W 3 , a protecting group, or the formula:
wherein:
R y is independently H, W 3 , R 2 or a protecting group;
R 1 is independently H or alkyl of 1 to 18 carbon atoms;
R 2 is independently H, R 1 , R 3 or R 4 wherein each R 4 is independently substituted with 0 to 3 R 3 groups or taken together at a carbon atom, two R 2 groups form a ring of 3 to 8 carbons and the ring may be substituted with 0 to 3 R 3 groups;
R 3 is R 3a , R 3b , R 3c or R 3d , provided that when R 3 is bound to a heteroatom, then R 3 is R 3c or R 3d ;
R 3a is F, Cl, Br, I, —CN, N 3 or —NO 2 ;
R 3b is Y 1 ;
R 3c is —R x , —N(R x )(R x ), —SR x , —S(O)R x , —S(O) 2 R x , —S(O)(OR x ), —S(O) 2 (OR x ), —OC(Y 1 )R x , —OC(Y 1 )OR x , —OC(Y 1 )(N(R x )(R x )), —SC(Y 1 )R x , —SC(Y 1 )OR x , —SC(Y 1 )(N(R x )(R x )), —N(R x )C(Y 1 )R x , —N(R x )C(Y 1 )OR x , or —N(R x )C(Y 1 )(N(R x )(R x ));
R 3d is —C(Y 1 )R x , —C(Y 1 )OR x or —C(Y 1 )(N(R x )(R x ));
R 4 is an alkyl of 1 to 18 carbon atoms, alkenyl of 2 to 18 carbon atoms, or alkynyl of 2 to 18 carbon atoms;
R 5 is R 4 wherein each R 4 is substituted with 0 to 3 R 3 groups;
W 3 is W 4 or W 5 ;
W 4 is R 5 , —C(Y 1 )R 5 , —C(Y 1 )W 5 , —SO M2 R 5 , or —SO M2 W 5 ;
W 5 is carbocycle wherein W 5 is independently substituted with 0 to 3 R 2 groups;
W 6 is W 3 independently substituted with 1, 2, or 3 A 3 groups;
M2 is 0, 1 or 2;
M12a is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;
M12b is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12;
M1a, M1c, and M1d are independently 0 or 1; and
M12c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12.
2 . The conjugate of claim 1 that is of formula 211 or 212:
or a pharmaceutically acceptable salt or solvate thereof;
wherein:
one A 0 is A 1 .
3 . The conjugate of claim 1 wherein each A 3 is of the formula:
4 . The conjugate of claim 1 wherein each A 3 is of the formula:
wherein the phenyl carbocycle is substituted with 0, 1, 2, or 3 R 2 groups.
5 . The conjugate of claim 1 wherein each A 3 is of the formula:
wherein:
Y 1a is O or S; and
Y 2a is O, N(R 2 ) or S.
6 . The conjugate of claim 1 wherein A 0 is of the formula:
wherein each R is independently alkyl.
7 . The conjugate of claim 2 wherein each A 3 is of the formula:
8 . The conjugate of claim 2 wherein each A 3 is of the formula:
wherein the phenyl carbocycle is substituted with 0, 1, 2, or 3 R 2 groups.
9 . The conjugate of claim 2 wherein each A 3 is of the formula:
wherein:
Y 1a is O or S; and
Y 2a is O, N(R 2 ) or S.
10 . The conjugate of claim 2 wherein A 0 is of the formula:
wherein each R is independently alkyl.
11 . A pharmaceutical composition comprising a pharmaceutical excipient and a conjugate as described in claim 1 , or a pharmaceutically acceptable salt or solvate thereof.
12 . A pharmaceutical composition comprising a pharmaceutical excipient and a conjugate as described in claim 2 , or a pharmaceutically acceptable salt or solvate thereof.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.